These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18676327)

  • 1. Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
    Iott MJ; Corsini MM; Miller RC
    Clin J Oncol Nurs; 2008 Aug; 12(4):599-605. PubMed ID: 18676327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
    Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
    Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.
    Neoptolemos JP; Stocken DD; Dunn JA; Almond J; Beger HG; Pederzoli P; Bassi C; Dervenis C; Fernandez-Cruz L; Lacaine F; Buckels J; Deakin M; Adab FA; Sutton R; Imrie C; Ihse I; Tihanyi T; Olah A; Pedrazzoli S; Spooner D; Kerr DJ; Friess H; Büchler MW;
    Ann Surg; 2001 Dec; 234(6):758-68. PubMed ID: 11729382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
    Ohigashi H; Ishikawa O; Eguchi H; Takahashi H; Gotoh K; Yamada T; Yano M; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K
    Ann Surg; 2009 Jul; 250(1):88-95. PubMed ID: 19561477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
    Hattangadi JA; Hong TS; Yeap BY; Mamon HJ
    Cancer; 2009 Aug; 115(16):3640-50. PubMed ID: 19514088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    You DD; Lee HG; Heo JS; Choi SH; Choi DW
    J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma.
    Saidi RF; Jacobs MJ
    Ann Surg; 2009 May; 249(5):865; author reply 865-6. PubMed ID: 19387303
    [No Abstract]   [Full Text] [Related]  

  • 9. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
    Evans DB; Varadhachary GR; Crane CH; Sun CC; Lee JE; Pisters PW; Vauthey JN; Wang H; Cleary KR; Staerkel GA; Charnsangavej C; Lano EA; Ho L; Lenzi R; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2008 Jul; 26(21):3496-502. PubMed ID: 18640930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
    Okabayashi T; Nishimori I; Nishioka A; Yamashita K; Sugimoto T; Dabanaka K; Maeda H; Kohsaki T; Ogawa Y; Kobayashi M; Onishi S; Hanazaki K
    Oncol Rep; 2008 Sep; 20(3):651-6. PubMed ID: 18695919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
    Piperdi M; McDade TP; Shim JK; Piperdi B; Kadish SP; Sullivan ME; Whalen GF; Tseng JF
    HPB (Oxford); 2010 Apr; 12(3):204-10. PubMed ID: 20590888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for pancreatic cancer: current status.
    Regine WF; John WJ; Mohiuddin M
    Front Biosci; 1998 Nov; 3():E186-92. PubMed ID: 9820740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
    Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK
    Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
    McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R
    J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
    Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
    Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
    Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
    Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW
    Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of adjuvant chemoradiotherapy in the therapeutic strategy of exocrine adenocarcinoma of the pancreas].
    Mornex F; Partensky C; Bedenne L
    Cancer Radiother; 1997; 1(5):542-6. PubMed ID: 9587387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
    Drudi F; Tassinari D; Giuliani J; Ridolfi C; Gianni L; Tamburini E; Fantini M; Santelmo C; Barzotti E; Lotti N; Ravaioli A
    Recenti Prog Med; 2013 Feb; 104(2):80-5. PubMed ID: 23535964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.